Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Stock price

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Jun 08, 2020 2:56pm

121 Views

Post# 31125424

RE:Stock price

Instead of crying about it on StockHouse sell your shares if any and move on. No one cares that your Impatient.

Raiders11 wrote: Wow all markets up 40% or more and this piece of shiiiit can't even hold a quarter of a penny gain and some of you think this will go up to 30 cents or more,good luck with that,I wish it would happen but nobody is interested in this covid cure at all,evident in our share price!

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue